Human Tumor suppressor p53-binding protein 1 (TP53BP1) ELISA Kit
| Product Name | Human Tumor suppressor p53-binding protein 1 (TP53BP1) ELISA Kit |
|---|---|
| Description | TP53BP1 has a predicted molecular mass of 217 kD and shows homology in its C-terminal 247 amino acids to the C terminus of the tumor suppressor protein BRCA1. TP53BP1 was present in both the cytoplasm and nucleus in some cells and only in the nucleus in others. Furthermore, there were 2 nuclear staining patterns, one homogeneous staining and the other dot staining.TP53BP1 was required for p53 accumulation, G2/M checkpoint arrest, and the intra-S-phase checkpoint in response to ionizing radiation. TP53BP1 played a partially redundant role in phosphorylation of the downstream checkpoint effector proteins BRCA1 and CHK2 but was required for the formation of BRCA1 foci in a hierarchical branched pathway for the recruitment of repair and signaling proteins to sites of DNA damage. This assay has high sensitivity and excellent specificity for detection of Human TP53BP1. No significant cross-reactivity or interference between Human TP53BP1 and analogues was observed. |
| Synonyms | 53BP1, FLJ41424, MGC138366, p202, tumor protein 53-binding protein, 1|tumor protein p53-binding protein, 1 |
| Method | Sandwich ELISA |
| Detection Range | 0.312-20 ng/mL |
| Sensitivity | 0.138 ng/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background | TP53BP1 has a predicted molecular mass of 217 kD and shows homology in its C-terminal 247 amino acids to the C terminus of the tumor suppressor protein BRCA1. TP53BP1 was present in both the cytoplasm and nucleus in some cells and only in the nucleus in others. Furthermore, there were 2 nuclear staining patterns, one homogeneous staining and the other dot staining.TP53BP1 was required for p53 accumulation, G2/M checkpoint arrest, and the intra-S-phase checkpoint in response to ionizing radiation. TP53BP1 played a partially redundant role in phosphorylation of the downstream checkpoint effector proteins BRCA1 and CHK2 but was required for the formation of BRCA1 foci in a hierarchical branched pathway for the recruitment of repair and signaling proteins to sites of DNA damage. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.